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Summary The prevalence of chronic obstructive pulmonary disease (COPD) in
women is increasing worldwide. Women may have greater susceptibility to COPD
progression than men, and differences in efficacy and safety of respiratory
medications by gender are largely unexplored. We aimed to determine whether
the response to treatment in women with COPD differed from men in a large, 1-year
double-blind trial (‘TRISTAN’). In a sensitivity analysis, we compared 539 male and
180 female COPD patients, who were randomized to the salmeterol/fluticasone
combination 50/500mcg bid or placebo for 12 months. Combination therapy
improved pre-treatment FEV1 significantly more than placebo in women by 152ml
(95% confidence interval 95–208) and in men by 127ml (94–159). Similarly, a
reduction in COPD exacerbation rates of 31% in women (9–48%) and of 23% in men (8–
35%) was observed. Combination therapy reduced COPD exacerbations requiring
treatment with oral corticosteroids by 36% in women and by 41% in men. Finally,
combination treatment produced a better improvement in health status than
placebo with a decrease in the SGRQ scores in women by 2.3 (4.6 – 0.1) and in
men by 2.1 (3.5 to 0.8). No gender interaction was found for any outcome.
Treatments were well tolerated with no difference in the frequency of adverse
events in women and men. In this trial, therapy with the salmeterol/fluticasone
combination produced significant improvements compared to placebo on all main
endpoints and the magnitude of these improvements was similar for both men and
women.
& 2004 Elsevier Ltd. All rights reserved.
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Introduction
In 2000, for the first time, the number of women
dying from chronic obstructive pulmonary disease
(COPD) in the US surpassed the number of men
dying from COPD.1 It is forecasted that this increase
in female COPD will be observed elsewhere.2,3 On
average, women smoke less and do not inhale
tobacco as frequently as men. It has therefore been
hypothesized that women are more susceptible to
the deleterious effects of smoking in their lungs,
and for a given history of smoking women may be
more likely than men to develop COPD.4,5 Gender
differences in the presentation of respiratory
disease have been recently and comprehensively
reviewed,6 and it is now well accepted that there
are differences between the sexes in the presenta-
tion and pathophysiology of COPD, as recognized in
other diseases.7 However, less effort has been
dedicated to examine gender effects in the efficacy
of respiratory medication and, to our knowledge,
gender effects in COPD medication have not been
investigated. The TRISTAN trial is a multi-centre,
randomized, double-blind, placebo-controlled,
parallel-group study of 1465 COPD patients treated
with either salmeterol 50mcg bd (an inhaled long-
acting b2-agonist), fluticasone 500mcg bd (an
inhaled corticosteroid), salmeterol/fluticasone
combination 50/500mcg bd or placebo for 12
months.8 By using the combination and placebo
arms of this trial, we investigated whether combi-
nation treatment is equally efficacious in women
and men.
Methods
The methods and the primary results of the TRISTAN
trial can be found elsewhere.8 Briefly, it was
designed to compare the efficacy of salmeterol/
fluticasone propionate combination (SFC; 50/
500mcg bd) with salmeterol alone (50mcg bd),
fluticasone propionate alone (500mcg bd) and
placebo, and to compare safety in all treatment
groups. Main endpoints were pre-bronchodilator
FEV1, rate of exacerbations, and Health Status as
determined using St George’s Respiratory Ques-
tionnaire. Inclusion criteria were COPD (ERS defini-
tion), age 40–79 years, 410 pack-years, pre-
bronchodilator FEV1 25–70% predicted, FEV1/FVC
o70%, poor reversibility (o10% predicted FEV1)
and chronic bronchitis with exacerbations in the
last 3 years.
Exclusion criteria were current diagnosis of
asthma, eczema, allergic rhinitis, use of systemic
steroids, antibiotics or change in COPD medication
during the last 4 weeks. Permitted COPD medica-
tions were salbutamol (relief medication), antic-
holinergic agents, and oral corticosteroids or
antibiotics in short courses for exacerbation treat-
ment, mucolytics (acetylcysteine), sodium cromo-
glycate (nedocromil sodium, ketotifen), and LTOT.
Non-permitted medications were oral short-acting
2-agonists, other inhaled corticosteroids, other
long-acting b2-agonists and combination broncho-
dilators (Combivent, Berodual, Duovent). The study
conclusion was that combining inhaled long-acting
b2-agonist and corticosteroid therapy produces
significantly better symptom control and lung
function at no greater risk of side effects than
using either component alone.
In this analysis we focused on the comparison of
the salmeterol/fluticasone combination to placebo
arms only. Our null hypothesis was that the
beneficial effects of salmeterol/fluticasone combi-
nation versus placebo in terms of pre-bronchodi-
lator FEV1, rate of exacerbations (all and severe
exacerbations), and health status are equally good
in women and men. As per consensus, rejection of
the null hypothesis would happen if a 20% differ-
ence in a quantitative variable (FEV1, number of
exacerbations, or SGRQ) by gender was found.
Repeated measures to analyse FEV1 and SGRQ, and
Poisson generalized linear model analysis of ex-
acerbations were conducted. Covariates included
smoking status, age, baseline FEV1, and centre.
Treatment, gender, and treatment by gender terms
were fitted in the model, and the predicted values
for men and women were obtained, along with
confidence intervals, and P-values of the signifi-
cance of the effect in both men and women.
Results
The TRISTAN trial was conducted at 196 centres in
25 countries and recruited 1974 patients, of whom
1465 received treatment. Of the 719 COPD patients
randomized to salmeterol/fluticasone combination
or placebo, 180 (25%) were women. There were no
differences by gender regarding duration of COPD
disease, withdrawal after randomization, previous
use of LABA, reversibility, FEV1% predicted, or
health status. Females were younger, more fre-
quently current smokers but with less pack-years,
more frequent previous users of ICS, had smaller
lung volumes and used more frequently relief medi-
cation than men (all Po0:05). With the possible
exception of smoking, the observed statistically
ARTICLE IN PRESS
1046 J. Vestbo et al.
significant differences in baseline characteristics by
gender were of little clinical relevance (Table 1).
The differential dropout after randomization was
almost identical in women and men. Only 26% of
women randomized to combination treatment
withdrew after randomization compared to 41%
women randomized to placebo. The same pattern
was observed in men, 24% versus 38%, respectively.
Combination therapy improved pre-treatment
FEV1 significantly more than placebo in women by
152ml, (95% Confidence interval 95–208) and in
men by 127ml, (94–159). This improved pre-
treatment FEV1 was equivalent in women and
men (P-value 0.455 for the gender interaction)
(Table 2). Similarly, a reduction in COPD exacerba-
tion rates of 31% in women (9–48%) and of 23% in
men (8–35%) was observed, with a non-significant
P-value 0.520 for the gender interaction (Fig. 1). In
addition, combination therapy reduced COPD ex-
acerbations requiring treatment with oral corticos-
teroids, the yearly rate being reduced by 36% in
women compared to placebo (9–55%) and by 41% in
men (25–53%), P-value 0.695 for the gender
interaction (Fig. 2). Combination treatment pro-
duced a significantly better improvement in health
status than placebo with a decrease in the SGRQ
scores in women by 2.3 (4.6 to 0.1) and in men
by 2.1 (3.5 to 0.8). This improved health
status was again equivalent in women and men,
P-value 0.904 for the gender interaction.
Finally, the frequency and severity of adverse
events were analysed by gender (Table 3). Combi-
nation treatment was well tolerated with no
significant difference between women and men in
the number of patients reporting an adverse event
during treatment. The exception was for an
increased prevalence of oropharyngeal candidiasis
in both women and men randomized to combina-
tion treatment. Throat irritation in women on
combination treatment was frequently reported
(11%).
Although not shown in this paper, there was again
no gender interaction in the comparison versus
placebo of the treatment arms with single compo-
nents salmeterol 50mcg and fluticasone combina-
tion 500mcg twice.
Discussion
We did not find differences between women and
men with COPD in the efficacy and safety outcomes
in a trial comparing the salmeterol/fluticasone
propionate combination versus placebo. Improve-
ments in pulmonary function, frequency of
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Table 1 Demographic and baseline characteristics of the Tristan participants randomized to salmeterol/
fluticasone combination or placebo, in women and men.
Characteristic Females Males P-valuesn
Number 180 539
Withdrawal after randomization 61 (34%) 168 (31%) 0.498
Age mean (SD) 61 (8.6) 64 (8.5) o0.001
Duration of disease
o5 years 52 (29%) 124 (23%)
5–10 69 (38%) 201 (37%)
10–15 30 (17%) 110 (20%)
X15 years 29 (16%) 104 (19%) 0.301
Current smoker n (%) 101 (56%) 256 (47%) 0.045
Mean pack years smoked (SD) 35 (18) 45 (23) o0.001
Previous ICS use n (%) 107 (59%) 259 (48%) 0.008
Previous LABA use n (%) 67 (37%) 220 (41%) 0.394
Pre-treatment FEV1 ml (SD) 1020 (392) 1376 (501) o0.001
Pre-bronchodilator FEV1% pred (SD) 45.0 (14.3) 44.3 (14.2) 0.572
Reversibility (% predicted FEV1) (SD) 4.42 (5.96) 4.89 (4.07) 0.180
Post-bronchodilator FEV1 ml (SD) 1117 (407) 1494 (511) o0.001
Pre-treatment FVC ml (SD) 1866 (559) 2737 (775) o0.001
Mean total SGRQ score (SD) 47.4 (15.6) 47.0 (16.3) 0.791
Median use of relief med./day 3.0 2.1 0.005
Mean no. awakenings/week (SD) 2.9 (4.8) 3.1 (5.2) 0.664
ICS: inhaled corticosteroids; LABA: long-acting b2-agonist; FEV1: forced expiratory volume in one second; FVC: forced vital
capacity; SGRQ: St. George’s Respiratory Questionnaire; SD: standard deviation.
nP-values for the comparison female versus male.
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exacerbations and health status were of identical
direction and similar magnitude in both sexes.
Similarly, safety results were of similar magnitude
in both arms in women and men, although women
reported more frequently adverse events than
men. These results are comforting for the way
medicine is usually practiced and may stimulate
further analyses on respiratory drugs and gender.
From an epidemiological perspective, COPD is
transforming from a disorder seen in elderly
smoking men, to affect more women and probably
at a younger age.9 Regretfully, women were
systematically excluded from RCTs until very
recently. Only since 1998 the FDA requested that
all NIH funded safety and efficacy trials should
include women. Recent non-pharmacological
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Table 2 Effect of Combination treatment versus placebo over 52 weeks on trial outcomes pre-treatment FEV1
and health status, by gender.
Outcome measures Females (n ¼ 180) Males (n ¼ 539)
Combination Placebo Combination Placebo
Pre-treatment FEV1 ml
N 84 92 261 261
Baseline, raw mean (SE) 994 (384) 1042 (402) 1409 (534) 1336 (468)
Adjusted, mean (SE) 1397 (21) 1245 (21) 1405 (12) 1279 (12)
Treatment difference (CI) 152 (95, 208) 127 (94, 159)
P-value o0.001 o0.001
Gender interaction 0.455
SGRQ total score
N 78 82 242 236
Baseline, raw mean (SE) 46.2 (16.7) 48.5 (14.5) 47.3 (15.5) 46.2 (16.8)
Adjusted, mean (SE) 43.2 (0.9) 45.5 (0.9) 44.7 (0.5) 46.9 (0.5)
Treatment difference (CI) 2.3 (4.6, 0.1) 2.1 (3.5, 0.8)
P-value 0.055 0.002
Gender interaction 0.904
Combination: salmeterol/ fluticasone combination (50/500mcg twice daily); FEV1: forced expiratory volume in one second; SE:
standard error; CI: 95% confidence interval; SGRQ: St. Georges’ Respiratory Questionnaire: a negative value represents an
improvement in health status.
Figure 1 Total exacerbation rate. Figure 2 Rate of exacerbations requiring treatment with
oral corticosteroids.
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interventions in COPD have explored on gender
differences with inconclusive results.10–12 Goodman
et al.13 have found that women are less likely than
men to perform acceptable metered-dose inhaler
use but this has little relevance to the present
study where we used the Diskus device. Recent
placebo-controlled tiotropium trials have been
analysed with focus on the influence of gender on
outcomes. Findings have only been reported as
abstract14 but seem to indicate less effect of
tiotropium on exacerbations in women.
In asthma, Mohamed et al.15 studied race and
gender effects on salbutamol pharmacodynamics in
30 patients with moderate asthma (15 blacks, 15
whites, 16 men, 14 women). No important racial or
gender differences in salbutamol-evoked FEV1 or
percent-predicted FEV1 were evident, although
females tended to be more sensitive compared to
males. Convery et al.16 investigated in a small
sample of patients the effect of FP and gender on
airway responsiveness, and found a better outcome
in asthmatic men. The multiple linear regression
analysis showed that the magnitude of the steroid
effect was significantly greater in males than in
females (3.2 versus 1.2 doublings, respectively, of
the PD20 geometric mean). They concluded that
inhaled corticosteroids caused a steadily increasing
improvement in airway responsiveness over a 6-
week period, which was better in men but lost
almost immediately on treatment cessation. These
findings may, however, reflect that airway respon-
siveness in general differs between men and
women. Leynaert et al.17 found that young women
were more hyperresponsive than men. When airway
hyperresponsiveness was defined as PD20o4mg/ml
methacholine, 37.3% of women were hyperrespon-
sive in contrast to 18.6% of men.
Gender analyses of drugs in respiratory disease in
general, and in COPD in particular, are relevant.
Differences in efficacy and safety of respiratory
drugs might indicate differences between the sexes
in the presentation and pathophysiology of COPD,
as recognized in other diseases. Not only do women
represent half of mankind, but they also take more
than their share of the increasing COPD burden
worldwide. Chapman et al.18 elegantly reported
that North American primary care doctors under-
diagnosed COPD frequently, but reluctantly diag-
nosed COPD in women even with evidence of
objective airflow obstruction.
Our study was powered to detect a 100ml
difference in FEV1 in the total intention-to-treat
population. For this reason power to detect gender
differences in the effect of the salmeterol/flutica-
sone combination therapy is somewhat limited as
reflected in the 95% confidence intervals for
treatment effects shown in Table 2. With the point
estimates given, however, we feel confident that no
major gender differences are present.
To conclude, it appears that in this trial the
salmeterol/fluticasone combination therapy pro-
duced significant improvements compared to pla-
cebo on all main endpoints in female and male
COPD patients. There was no significant treatment
interaction with gender and the magnitude of these
improvements was similar for both men and
women. The search for gender interactions should
be explored in other respiratory medications.
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Table 3 General and most common drug-related adverse events during treatment with the salmeterol/
fluticasone combination or placebo, by gender.
Event, n (%) Females (n ¼ 180) Males (n ¼ 539)
Combination Placebo Combination Placebo
N (%) 88 92 270 269
Any adverse event 76 (86%) 75 (82%) 209 (77%) 208 (77%)
Serious adverse event 12 (14%) 12 (13%) 50 (19%) 42 (16%)
Drug-related adverse event 13 (15%) 15 (16%) 45 (17%) 34 (13%)
Withdrawn due to adverse event 10 (11%) 21 (23%) 31 (11%) 45 (17%)
Candidiasis mouth/throat 7 (8%) 3 (3%) 20 (7%) 3 (1%)
Nausea and vomiting 1 (1%) 1 (1%) 0 2 (o1%)
COPD exacerbation 49 (56%) 53 (58%) 127 (47%) 139 (52%)
Lower respiratory infection 9 (10%) 5 (5%) 22 (8%) 14 (5%)
Throat irritation 10 (11%) 1 (1%) 12 (4%) 10 (4%)
Headaches 4 (5%) 4 (4%) 11 (4%) 14 (5%)
Salmeterol/fluticasone combination in women and men with COPD 1049
GlaxoSmithKline group of companies. Funding for
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